Can an insulin drip be discontinued without bridging when the rate is low and blood glucose levels are well-controlled?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 25, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

It is not recommended to stop an insulin drip without bridging, even at a very low rate with tight blood glucose control. When discontinuing an intravenous insulin infusion, a transition protocol is associated with less morbidity and lower costs of care, and is therefore recommended 1. This protocol involves administering a dose of subcutaneous basal insulin 2 hours before the intravenous infusion is discontinued, with the dose calculated based on the insulin infusion rate during the last 6 hours when stable glycemic goals were achieved. Some key points to consider when transitioning from intravenous to subcutaneous insulin include:

  • Calculating the dose of basal insulin based on the insulin infusion rate during the last 6 hours when stable glycemic goals were achieved 1
  • Ensuring correct dosing when using concentrated insulin (U-200, U-300, or U-500) in the inpatient setting, by utilizing an individual pen and cartridge for each patient and by meticulous supervision of the dose administered 1
  • Adopting and implementing a hypoglycemia prevention and management protocol to prevent episodes of hypoglycemia among inpatients 1 Abrupt discontinuation of insulin infusion without bridging can lead to dangerous hyperglycemia and potentially diabetic ketoacidosis in type 1 diabetics, as the body will have no insulin coverage once the IV insulin is rapidly cleared. In clinical practice, it is essential to prioritize caution and follow established protocols to ensure a smooth transition from intravenous to subcutaneous insulin, minimizing the risk of complications and optimizing patient outcomes.

From the Research

Stopping Insulin Drip Without Bridging

  • The provided studies do not directly address the question of stopping an insulin drip without bridging when the rate is very low and blood glucose levels are tight 2, 3, 4, 5, 6.
  • However, the studies discuss the importance of achieving and maintaining glycemic control in hospitalized patients, and the use of continuous intravenous (i.v.) insulin infusions or intermittent subcutaneous (s.c.) basal-bolus plus correction injections as preferred methods for managing hyperglycemia 2.
  • The studies also highlight the need for proactive management of hyperglycemia and the importance of considering factors such as the severity of illness, medications, and inconsistent dietary intake when determining the aggressiveness of therapy to manage blood glucose levels 2.
  • Additionally, the studies discuss the benefits of using insulin analogs, such as improved physiologic profile, greater convenience, reduced risk of hypoglycemia, and less weight gain, which may be relevant to considerations around stopping an insulin drip without bridging 3, 4, 5, 6.

Considerations for Stopping Insulin Drip

  • When considering stopping an insulin drip without bridging, it is essential to take into account the individual patient's circumstances, including their blood glucose levels, insulin requirements, and overall health status.
  • The studies emphasize the importance of careful monitoring and management of blood glucose levels to prevent hypoglycemia and other complications 2, 3, 4, 5, 6.
  • However, without specific guidance from the provided studies, it is not possible to provide a definitive answer to the question of stopping an insulin drip without bridging when the rate is very low and blood glucose levels are tight.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Hyperglycemia management in the hospital setting.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2007

Research

Insulin analog therapy: improving the match with physiologic insulin secretion.

The Journal of the American Osteopathic Association, 2009

Research

A review of human and analogue insulin trials.

Diabetes research and clinical practice, 2007

Related Questions

What dose of insulin is required for a blood glucose level of 452 milligrams per deciliter (mg/dL)?
What is the recommended inpatient management for severe hyperglycemia without Diabetic Ketoacidosis (DKA)/Hyperglycemic Hyperosmolar State (HHS), including choice of basal-bolus insulin versus insulin infusion, starting dose for insulin-naïve patients, and monitoring parameters?
How should hyperglycemia be managed in a 72‑year‑old male with type 2 diabetes mellitus, chronic heart failure, and continuous enteral tube feeding who is receiving insulin lispro (rapid‑acting insulin) 5 U three times daily and insulin glargine (long‑acting insulin) 5 U twice daily, with capillary glucose consistently 200–400 mg/dL in a nursing home?
How should I adjust the diabetes regimen for a 69‑year‑old man with type 2 diabetes, hypertension, hyperlipidemia, vitamin‑D deficiency, stable hemoglobin A1c 7.8%, normal estimated glomerular filtration rate, who is currently taking insulin aspart (Novolog) 10 U before breakfast and 5 U at bedtime, insulin glargine (Lantus) 44 U twice daily, semaglutide (Ozempic) 2 mg weekly, and glipizide 10 mg twice daily?
How to manage a patient with hyperglycemia, impaired renal function, fluid overload, and elevated B-Type Natriuretic Peptide?
What is the cause of upper lip swelling (edema)?
Can tranexamic acid (TXA) stop a gastrointestinal (GI) bleed?
Can insulin infusion be discontinued without bridging therapy?
What is the clinical significance of an endometrial thickness of 0.5 centimeters (cm) and how does it correlate with prior ultrasound results?
What are the implications of Sickle Cell Disease (SCD) in pediatrics?
What are the adverse effects of Aminoglycosides?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.